Blood Test for Early Diagnosis of Alzheimer’s Disease
暂无分享,去创建一个
[1] Nick C Fox,et al. Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.
[2] Susan M Resnick,et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.
[3] M. Weiner,et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.
[4] Anders Wallin,et al. Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment , 2010, Neurobiology of Aging.
[5] P. Deyn,et al. No correlation between time-linked plasma and CSF Aβ levels , 2009, Neurochemistry International.
[6] L. Buée,et al. Association of plasma amyloid β with risk of dementia , 2009, Neurology.
[7] Fiona Crawford,et al. Serum β-Amyloid Correlates with Neuropsychological Impairment , 2009, Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition.
[8] Daniel Paris,et al. Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer's disease. , 2008, Cytokine.
[9] H. Fukuyama,et al. Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease , 2008, Proceedings of the National Academy of Sciences.
[10] J. Beijnen,et al. Serum amyloid beta peptides in patients with dementia and age-matched non-demented controls as detected by surface-enhanced laser desorption ionisation-time of flight mass spectrometry (SELDI-TOF MS). , 2008, Current clinical pharmacology.
[11] G. Perry,et al. Antigen–antibody dissociation in Alzheimer disease: a novel approach to diagnosis , 2008, Journal of neurochemistry.
[12] J. Becker,et al. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study , 2008, Neurology.
[13] M. Barcikowska,et al. Plasma beta amyloid and cytokine profile in women with Alzheimer's disease. , 2008, Neuro endocrinology letters.
[14] B. Hyman,et al. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. , 2008, Archives of neurology.
[15] Georg Kemmler,et al. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine , 2008, Neurobiology of Aging.
[16] V. Mathura,et al. The influence of diagnosis, intra- and inter-person variability on serum and plasma Aβ levels , 2007, Neuroscience Letters.
[17] R. Tibshirani,et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.
[18] K. Blennow,et al. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies , 2007, Neurology.
[19] I. Mook‐Jung,et al. Serum Anti-Amyloid-β Antibodies and Alzheimer's Disease in Elderly Korean Patients , 2007, The Journal of international medical research.
[20] O. Forlenza,et al. Abnormal APP processing in platelets of patients with Alzheimer’s disease: correlations with membrane fluidity and cognitive decline , 2007, Psychopharmacology.
[21] A. Fagan,et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.
[22] Henrik Zetterberg,et al. Alzheimer's disease , 2006, The Lancet.
[23] Zhikai Cao,et al. Low Avidity and Level of Serum Anti-Aβ Antibodies in Alzheimer Disease , 2006, Alzheimer disease and associated disorders.
[24] G. Ortiz,et al. Altered β-Amyloid Precursor Protein Isoforms in Mexican Alzheimer’s Disease Patients , 2006, Disease markers.
[25] B. Hyman,et al. Autoantibodies to Redox-modified Oligomeric Aβ Are Attenuated in the Plasma of Alzheimer's Disease Patients* , 2005, Journal of Biological Chemistry.
[26] H. Möller,et al. Decreased serum amyloid β1–42 autoantibody levels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1–42 peptide , 2005, Biological Psychiatry.
[27] E. Zamrini,et al. Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Aβ and RAGE peptides , 2004, Neurobiology of Aging.
[28] A. Hofman,et al. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. , 2004, Archives of neurology.
[29] S. Wisniewski,et al. Plasma and cerebrospinal fluid α1‐antichymotrypsin levels in Alzheimer's disease: Correlation with cognitive impairment , 2003, Annals of neurology.
[30] L. Rozzini,et al. Early stages of probable Alzheimer disease are associated with changes in platelet amyloid precursor protein forms , 2002, Neurological Sciences.
[31] N. Relkin,et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals , 2002, Experimental Gerontology.
[32] G. Lenzi,et al. Amyloid precursor protein in platelets , 2001, Neurology.
[33] S. McIlroy,et al. Association of serum AACT levels and AACT signal polymorphism with late‐onset Alzheimer's disease in Northern Ireland , 2000, International journal of geriatric psychiatry.
[34] G. Annoni,et al. Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? , 2000, Journal of Neuroimmunology.
[35] L. Thal,et al. Blood Levels of Alpha-1-Antichymotrypsin and Risk Factors for Alzheimer’s Disease: Effects of Gender and Apolipoprotein E Genotype , 2000, Dementia and Geriatric Cognitive Disorders.
[36] E. Matsubara,et al. Lipoprotein‐free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome , 1999, Annals of neurology.
[37] L. Vignolo,et al. Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. , 1998, Archives of neurology.
[38] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[39] E. Porcellini,et al. Elevated plasma levels of alpha-1-anti-chymotrypsin in age-related cognitive decline and Alzheimer's disease: a potential therapeutic target. , 2008, Current pharmaceutical design.
[40] R. Petersen,et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. , 2007, Archives of neurology.
[41] T. J. Grabowski,et al. Proteome-based plasma biomarkers for Alzheimer's disease , 2007 .
[42] A. Hofman,et al. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. , 2006, The Lancet. Neurology.
[43] I. Kloszewska,et al. Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. , 2005, Acta neurobiologiae experimentalis.
[44] J. Growdon,et al. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. , 2003, Archives of neurology.
[45] L S Honig,et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. , 2003, Neurology.
[46] C. Caltagirone,et al. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. , 2002, Archives of neurology.
[47] H. Wiśniewski,et al. Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease , 2000 .
[48] G. Sanders,et al. Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease. , 1999, Genetic testing.
[49] E. Oguni,et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. , 1996, Journal of the neurological sciences.
[50] A. Kling,et al. Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia. , 1995, Neurobiology of aging.
[51] H. Wiśniewski,et al. Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease. , 1994, Neurobiology of aging.